A pilot study on area under curve of mycophenolic acid as a guide for its optimal use in renal transplant recipients

Indian Journal of Medical Research

Volumn 135, Issue 1, 2012, Pages 84-91

  Sarangi, S C ^a   Reeta, K H ^a   Agarwal, S K ^a   Kaleekal, T ^a   Guleria, S ^a   Gupta, Y K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Adverse drug events; Area under the curve (AUC); Health related quality of life; Mycophenolic acid (MPA); Renal transplant

Indexed keywords

MYCOPHENOLIC ACID; STEROID; TACROLIMUS;

ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CELLULITIS; CHICKENPOX; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEHYDRATION; DIABETES MELLITUS; DIARRHEA; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; GASTROINTESTINAL QUALITY OF LIFE INDEX; GIARDIASIS; GRAFT RECIPIENT; HEPATITIS B; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OTITIS MEDIA; POLYOMAVIRUS INFECTION; RATING SCALE; SEPSIS; SEPTICEMIA; SIDE EFFECT; STOMACH PH; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VOMITING; WOUND INFECTION;

ADULT; AREA UNDER CURVE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PILOT PROJECTS; TACROLIMUS;

EID: 84857828290     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: 10.4103/0971-5916.93429     Document Type: Article

References (29)

1. Agarwal SK, Srivastava RK. Chronic kidney disease in India: Challenges and solutions. Nephron Clin Pract 2009; 111: c197-c203.
2. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-75.
3. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-5.
4. Salvadori M, Holzer H, de Mattos A, Sollinger H, Arns W, Oppenheimer F, et al. The ERL B301 Study Groups. Entericcoated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004; 4: 231-6.
5. Barbari AG, Stephan AG, Masri MA. Calcineurin inhibitorfree protocols: Risks and benefits. Saudi J Kidney Dis Transpl 2007; 18: 1-23.
6. Lehmkuhl H, Hummel M, Kobashigawa J, Ladenburger S, Rothenburger M, Sack F, et al. Enteric-coated mycophenolatesodium in heart transplantation: efficacy, safety, and pharmacokinetic compared with mycophenolate mofetil. Transplant Proc 2008; 40: 953-5.
7. Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation 2008; 85: 1675-85.
8. Miura M, Satoh S, Niioka T, Kagaya H, Saito M, Hayakari M, et al. Limited sampling strategy for simultaneous estimation of the area under the concentration-time curve of tacrolimus and mycophenolic acid in adult renal transplant recipients. Ther Drug Monit 2008; 30: 52-9.
9. Jeong H, Kaplan B. Therapeutic monitoring of mycophenolate mofetil. Clin J Am Soc Nephrol 2007; 2: 184-91.
10. Cox VC, Ensom MH. Mycophenolate mofetil for solid organ transplantation: Does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit 2003; 25: 137-57.
11. Ciancio G, Burke GW, Gaynor JJ, Roth D, Sageshima J, Kupin W, et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. Transplantation 2008; 86: 67-74.
12. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 Suppl 1): S1-266.
13. Perez-Valdivieso JR, Bes-Rastrollo M, Monedero P, de Irala J, Lavilla FJ. Prognosis and serum creatinine levels in acute renal failure at the time of nephrology consultation: an observational cohort study. BMC Nephrol 2007; 8: 14.
14. Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis 2007; 50: 169-80.
15. Dimenäs E, Glise H, Hallerbäck B, Hernqvist H, Svedlund J, Wiklund I. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol 1995; 30: 1046-52.
16. Bolin P, Tanriover B, Zibari GB, Lynn ML, Pirsch JD, Chan L, et al. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients. Transplantation 2007; 84: 1443-51.
17. Headache Research Report. APPENDIX M, Gastrointestinal Symptom Rating Scale (GSRS). David McMillin, MA, Meridian Institute, October, 2001. Available from: http://www.meridianinstitute.com/reports/headache/Appendix%20N.pdf, accessed on January 18, 2008.
18. Eypasch E, Williams JI, Wood-Dauphinee S, Ure BM, Schmülling C, Neugebauer E, et al. Gastrointestinal Quality of Life Index: development, validation and application of a new instrument. Br J Surg 1995; 82: 216-22.
19. Kleinman L, Kilburg A, Machnicki G, Faull R, Walker R, Prasad R, et al. Using GI-specific patient outcomes measures in renal transplant patients: validation of the GSRS and GIQLI. Qual Life Res 2006; 15:1223-32.
20. Budde K, Bauer S, Hambach P, Hahn U, Röblitz H, Mai I, et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant 2007; 7: 888-98.
21. Tedesco-Silva H, Felipe CR, Park SI, Pinheiro-Machado PG, Garcia R, Slade A, et al. Randomized crossover study to assess the inter- and intrasubject variability of morning mycophenolic acid concentrations from enteric-coated mycophenolate sodium and mycophenolate mofetil in stable renal transplant recipients. Clin Transplant 2010; 24: E116-23.
22. Neumann I, Fuhrmann H, Kanzler M, Fang IF, Jaeger A, Graf H, et al. Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft. Expert Opin Pharmacother 2008; 9: 879-86.
23. Djabarouti S, Duffau P, Lazaro E, Chapouly C, Greib C, Viallard JF, et al. Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus. Expert Opin Pharmacother 2010; 11: 689-99.
24. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007; 46: 13-58.
25. Böhler T, Canivet C, Galvani S, Therville N, Salvayre R, Negre-Salvayre A, et al. Pharmacodynamic monitoring of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable kidney-allograft recipients. Int Immunopharmacol 2008; 8: 769-73.
26. van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261-6.
27. Kuypers DR, de Jonge H, Naesens M, de Loor H, Halewijck E, Dekens M, et al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, openlabel, prospective, clinical follow-up study in renal allograft recipients. Clin Ther 2008; 30: 673-83.
28. Mourad M, Malaise J, Chaib Eddour D, De Meyer M, König J, Schepers R, et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem 2001; 47: 1241-8.
29. Cofan F, Rosich E, Arias M, Torregrosa V, Oppenheimer F, Campistol JM. Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to entericcoated mycophenolate sodium. Transplant Proc 2007; 39: 2179-81.